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Value of immunogenicity 
studies of infl uenza 
vaccine in resource-
limited settings
The studies1,2 of Russian-backbone live 
attenuated infl uenza vaccine (LAIV) in 
children from Senegal and Bangladesh 
in The Lancet Global Health are 
welcome, in view of the high burden 
of infl uenza-associated morbidity and 
mortality in resource-limited settings. 
Although the lack of immunogenicity 
data is highlighted as a limitation 
by the authors, we feel that the 
importance of generating such data 
in future studies is underplayed. 
With the exception of one study3 
including children from South Africa, 
to our knowledge, no paediatric 
immunogenicity data exist from sub-
Saharan Africa for the Ann Arbor-based 
LAIV. This amounts to a signifi cant gap 
in knowledge of how an intranasal 
LAIV performs immunologically 
in these settings. Parallels can be 
drawn with the well-described poorer 
performance of live oral vaccines in 
resource-limited settings.
The lack of a single identified 
correlate of protection for LAIV should 
not deter future immunogenicity 
studies in resource-limited settings, 
especially using systems vaccinology 
approaches designed to dissect 
the complex interplay of innate 
and adaptive pathways following 
vaccination.4 John C Victor1 and 
colleagues propose that diff erences in 
nasopharyngeal ecology could explain 
differential LAIV performance. As 
methods to interrogate and integrate 
complex datasets evolve, testing such 
hypotheses becomes increasingly 
possible.
Although further efficacy studies 
of this vaccine in resource-limited 
settings are vital, in our view, studies 
probing more mechanistic aspects 
of LAIV performance are also crucial. 
Not only might such studies offer 
some explanation for the lack of 
efficacy seen in Senegal, but they 
might also underpin the design of 
future generations of LAIV for use in 
resource-limited settings. 
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